Global Japanese Encephalitis Market – Industry Trends and Forecast to 2029

Japanese Encephalitis Market Analysis and Size

The global japanese encephalitis market is expected to witness significant growth during the forecast period. Growing cases of mosquito-borne flavivirus diseases drives the Japanese encephalitis market. Moreover, increased awareness by WHO and government authorities for Japanese encephalitis vaccination and rise in prevalence of yellow fever, dengue and West Nile viruses will boost up the Japanese encephalitis market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global japanese encephalitis market in the forecast period 2022-2029. The expected CAGR of global japanese encephalitis market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 210 million in 2021, and it would grow upto USD 334.71 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Japanese encephalitis is the most important cause of viral encephalitis. It is caused by mosquito-borne flavivirus, related to the same genus as yellow fever, dengue and west nile viruses. The virus is found in pigs and birds and transmitted to humans through bites from the infected mosquitoes of the Culex species. It cannot spread from person to person. Symptoms of Japanese encephalitis include early symptoms such as headache, fever, and vomiting, common seizures, especially among children, mental status changes, movement disorders, neurologic symptoms, weakness, and might develop over the next few days.  

Report Scope and Market Segmentation

Global Japanese Encephalitis Market Dynamics

Drivers

• Increased Incidence of Japanese Encephalitis

According to the World Health Organization(WHO), the number of clinical cases of JE is estimated to be approximately 68,000 worldwide. With regards to this, the worldwide Japanese encephalitis vaccines is expected to grow at a healthy rate.  Thus, all these factors boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Clinical Research and Initiatives

Governments across the country are estimated to include Japanese encephalitis vaccine in national immunization programs, which is anticipated to be one of the major growth drivers in the forecast period. Increasing investments in R&D are creating the growth of the market. China and India are predominantly vulnerable to Japanese encephalitis in the Asia Pacific region. Thus, it drives the growth of the market.

• Increasing Demand for Retail Pharmacies

The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of Awareness about the disease

Japanese encephalitis is a type of disease that is not known properly or understood properly among patients and healthcare professionals. Lack of awareness leads to improper treatment which eventually decreases the patient recovery. Thus, in a way it hampers the market growth

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global japanese encephalitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global japanese encephalitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Japanese Encephalitis Market Scope

The global japanese encephalitis market is segmented on the basis of diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Blood Test
• IgM-Capture ELISA
• Cerebrospinal Fluid Test
• Others

Treatment

• Vaccination
• Supportive Care
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Japanese Encephalitis Market Regional Analysis/Insights

The global japanese encephalitis market is analysed and market size insights and trends are provided by diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global japanese encephalitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for global japanese encephalitis market throughout the forecasted period due to increased prevalence of encephalitis and increased number of pig farms, poultry farms and mosquito nuisance in the region.

North America dominates the market due to increase in investment from the government, private & public sectors and advanced healthcare technology & expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Japanese Encephalitis Market Share Analysis

The global japanese encephalitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global japanese encephalitis market.

Key players operating in the global japanese encephalitis market include:

• Adimmune Corp. (Taiwan)
• Bharat Biotech (India)
• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Allergan,Inc (Ireland)
• Dr. Reddy's Laboratories Ltd (India)
• Endo International plc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Sun Pharmaceutical Industries Ltd (India)
• Mylan N.V. (U.S.)
• Aurobindo Pharma (India)
• Valneva SE (France)
• GC Biopharma (South Korea)
• Biological E Limited (India)

SKU-53831